Researchers report that biosimilar use was not influenced by disease type but correlated with treatment sequence, shorter ...

The FDA has approved Celltrion's Eydenzelt, a new aflibercept biosimilar, enhancing treatment options for retinal diseases in the US.

A recent study confirms the stability of XSB-001 biosimilar for retinal diseases under realistic clinical handling conditions ...

A review of the safety of biosimilar DMARDs during pregnancy reveals critical evidence gaps and the need for informed clinical guidance.

The latest advancements in global biosimilar access include new treatments, strategic partnerships, and competitive market ...

Biosimilar approvals surge in the US and Europe, enhancing access to denosumab and aflibercept therapies while driving significant health care savings. In September 2025, biosimilars continued to ...

Omalizumab biosimilars promise significant savings for European health systems, enhancing access to vital therapies for patients with severe allergies. Biosimilars have been touted for years as a way ...